RGCC Group

events

2019 gathering

21 June 2019 - 22 June 2019

Unterägeri, Switzerland

RGCC staff, collaborators and branch officers will meet in Unterageri, near Zug, Switzerland to network, discuss new treatment protocols and hear about RGCC’s latest work.

Will you send me the results directly?

Please review our patient information leaflet

Patient info leaflet

Do I need to go through my GP to get a test?

Please review our patient information leaflet

Patient info leaflet

Can RGCC test for BRAF drugs?

Yes. Onconomics and Onconomics Plus tests can be used for Ras-Raf-MEK-Erk, dabrafenib, vemurafenib, c-Jun, C-Fos, trametinib and sorafenib.

Can the Oncotrace test differentiate between benign and malignant tumour cells?

Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

I have a patient whose specific tumour appears to have resisting populations because of the overexpression of the MDR1 gene. This can be reversed by the use of inhibitors of ABG2 pumps. What do I do?

In this case, a patient could proceed with ketoconazole as a first-line treatment, and verapanib as a second-line treatment. Verapanib can contribute to a fall in blood pressure.

Didn't find an answer to your question? Contact us directly.

Get in touch

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more

Events